Navigation Links
New strategy produces promising advance in cancer vaccines
Date:2/16/2010

Researchers at National Jewish Health and the University of Colorado School of Medicine have used a new strategy to develop cancer vaccines that are remarkably effective in mice. In the February 16 issue of the Proceedings of the National Academy of Sciences (PNAS), Kimberly Jordan, PhD, Jill Slansky, PhD, and John Kappler, PhD, report that 100 percent of the mice vaccinated with a peptide they developed remained alive and tumor-free for at least 60 days after inoculation with colon cancer cells. The research suggests a method for developing vaccines against a wide variety of cancers.

"We developed a peptide vaccine that binds strongly to naturally occurring T cells and stimulates them to vigorously attack cancer cells in mice," said Dr. Slansky, Associate Professor in the Integrated Immunology Department at National Jewish Health and the University of Colorado School of Medicine. "We can't guarantee that the vaccines we developed will make it to human trials, but our work does show that very effective cancer vaccines can be made, and outlines a new strategy for their development."

T cells are one of the prime sentinels of the immune system, which sound the alarm and help orchestrate the immune response. Ever since scientists found T cells inside tumors, they realized that the body does have a natural, albeit mild, immunity to cancer. The T cells inside tumors recognize antigens on the surfaces of tumor cells, but don't bind them strongly enough to sound an alarm or initiate a robust immune response.

Scientists have tried several strategies to stimulate those T cells, from general immune stimulants to synthetic variations on the naturally occurring antigens. Although some of the vaccines showed moderate results in animal models, none has proven effective in humans.

Dr. Slansky hypothesized that previous vaccine candidates were unsuccessful because they did not bind strongly enough to the T cells found inside tumors. As a result, the vaccines failed to stimulate the T cells into mounting an effective immune response. So, she, structural biologist Dr. Kappler, and Dr. Kimberly Jordan, the postdoctoral fellow whose work bridges the two labs, designed peptide vaccines that resemble naturally occurring antigens but bind more strongly to the T cells found inside tumors.

They evaluated five candidate peptide vaccines. They vaccinated mice twice with the candidate vaccines, then injected colon tumor cells into the mice a week later. The results were quite variable. Two of the vaccines protected few or no mice, three other vaccines kept 60%, 90% and 100% alive and tumor-free for 60 days.

The researchers tried to learn what distinguished the effective peptide vaccines from ineffective ones. They found that the ineffective vaccines strongly stimulated T cells that recognized the peptide vaccine but not any T cells that recognized antigen on the cancer cells.

The successful vaccines stimulated T cells that recognized both the peptide vaccine and the naturally occurring antigen. The successful antigens stimulated the growth of many more T cells than the ineffective ones. Those T cells were also highly activated and ready to attack, as evidenced by their production of cytokine signaling molecules. Remarkably, the most successful vaccine varied by only one amino acid from the naturally occurring antigen, which provoked almost no immune response.

"Our theory about the importance of the T cellpeptide bond was correct, but we learned that the peptides must also stimulate T cells that cross react with the existing antigens and produce a large population of activated T cells," said Dr. Kappler. "We believe this provides a very promising strategy for developing cancer vaccines. We are now working to learn why a single-amino-acid substitution makes such a huge difference in effectiveness."


'/>"/>

Contact: Adam Dormuth
dormutha@njhealth.org
303-398-1082
National Jewish Medical and Research Center
Source:Eurekalert

Related medicine news :

1. AWT Management Announce Aggressive Growth and Acquisition Strategy
2. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
3. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
4. More Than 100 Organizations Call for a National AIDS Strategy to End the Epidemic in the United States
5. Penn Veterinary Medicine report new strategy to create genetically modified animals
6. Novel strategy under study for aggressive leukemia
7. AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy
8. Blue Shield of California Names Vincent Coppola Vice President of Strategy and Business Development
9. Scientific Publications Strategy & Delivery Shifts from Marketing to Medical
10. Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
11. Computerized training of working memory is a promising therapeutic strategy in ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: